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Serum thymidine kinase (TK), zeta-associated protein of 70 kDa (ZAP-70) and CD38 levels have been shown to be correlated with 
survival in chronic lymphocytic leukaemia (CLL). Aim: To investigate the possible correlations between TK, ZAP-70 and CD38 lev-
els as prognostic markers in new diagnosed Rai stages of CLL patients. Methods: 120 CLL patients were enrolled. ELISA was 
used to measure serum TK level, flow cytomerty — to determine ZAP-70 and CD38 expression applying ZAP-70 Kit and mono-
clonal antibody to CD38, respectively. Results: Significantly higher levels of TK were found in the high progression group of CLL 
patients that corresponded to stage II (Rai classification). An elevated level of TK, CD38 and ZAP-70 together was also found 
in the II stage. The coefficient of correlation between CD38 and ZAP-70 is reliable (p < 0.001). There is also a correlation between 
the level of TK and the disease stage (p < 0.05). Other parameters do not show this correlation. Conclusion: The determination 
of TK, ZAP-70 and CD38 together allows patients susceptible to a possible stage of the disease, to be identified. Estimation of the 
factors at an early stage of the disease may allow an earlier commencement of treatment.
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Chronic lymphocytic leukaemia (CLL) follows a re-
markably heterogeneous course. While some patients 
survive for sustained periods of time without ever 
requiring treatment, others succumb rapidly to the 
aggressive and drug resistant disease [1]. The Rai 
and Binet [2, 21] clinical staging systems are valu-
able in classifying CLL patients into broad prognostic 
subgroups. Clinical stages, however, have some limita-
tions and this has led to a search for novel parameters 
with improved predictive power. The determination 
of thymidine kinase (TK), CD38 and zeta-associated 
protein of 70 kDa (ZAP-70) are increasingly utilized 
as prognostic factors for CLL [3–7]. ZAP-70 is a mo-
lecule normally expressed in T cells that helps them 
respond to antigen through their receptor. ZAP-70 pro-
tein was detected inside CLL cells by flow cytometry. 
The expression of ZAP-70 becomes discordant with 
increasing clinical stage [4–7, 10–12]. The CD38 ex-
pression is an independent prognostic marker [8, 9], 
also detected by flow cytometry. TK is a pyrimidine 
metabolic pathway enzyme and has a key role in the 
complementary alternative salvage pathway of deoxy-
ribonucleic acid (DNA) synthesis. This enzyme is re-
sponsible for the catalytic conversion of deoxythymi-
dine to deoxythymidine monophosphate [15]. To date, 
studies have shown that high TK levels are associated 
with an advanced clinical stage.
 The aim of this study was to test the hypothesis that 
elevated serum TK, CD38 and ZAP-70 levels depend 
on the stage of new CLL patients. 
MATERIALS AND METHODS
The study group consisted of 120 patients who 
were diagnosed with CLL for the first time. We have 
used the Rai classification for the estimation of clini-
cal stages. The selection of patients was carried out 
at the National Centre of Haematology in the period 
from July, 2007 to July, 2008. In our clinic the level 
of TK, ZAP-70 and CD38 were determined for all new 
CLL patients. Five millilitres of clotted peripheral blood 
were collected for the study, and serum samples 
were aliquoted, following centrifugation of whole 
blood at 600g for 10 min at room temperature, and 
stored at — 70 °C until testing. The most appropri-
ate thresholds to define ZAP-70 and CD38-positivity 
were controversial, the proposed cut-off levels being 
different [20, 22, 24]. Therefore, our study group was 
divided into three groups based on the degree of ac-
tivity of the disease, i.e. low, middle and high degree 
of activity. The research design, patients’ information 
and consent forms were approved by the Central Ethics 
commission. 
Thymidine kinase assay. TK is a cellular enzyme 
involved in a salvage pathway for DNA synthesis. 
As long as the level of TK in serum or plasma is low, 
it is better to base the measurements on the enzymatic 
activity [15, 16]. The TK levels are not routinely deter-
mined since this requires a time consuming immune 
assay. The new ELISA technique, (Divi Tum kit, Biovica, 
Sweden), was used for TK level detection. As substrate 
for TK the DiviTum assay uses Bromo-deoxyuridine 
which is phosphorylated to its monophosphate. In or-
der to immobilize and remove the monophosphate 
produced from the solution it is further phosphory-
lated to the tri-phosphate by kinases present in the 
reaction solution. The tri-phosphate is immobilized 
by DNA synthesis. After the TK activity incubation 
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is completed, the plate is washed and incubated with 
an anti-bromodeoxyuridine-antibody conjugated 
to alkaline phosphatase followed by a second wash. 
The alkaline phosphatase bound thus corresponds 
to the TK activity in the sample. The assay measures 
the activity of the enzyme, defined by the change 
of the absorbance. The minimal level for detection 
of ТК (sensitivity) was 100 ng/L in this method. The 
permitted TK levels variations were in the interval 
0 to 50 ng/L. We created a scale involving three ranges 
of TK as follows: TK 100—500 ng/L defines a low degree 
of activity of the disease. The middle degree of activity 
of the disease was defined when the level of TK was 
from 501 to 1000 ng/L. The high degree of activity 
of the disease was taken to be TK > 1000 ng/L.
ZAP-70 assay. One of the most differentially 
expressed genes is the gene encoding the zeta-asso-
ciated protein of 70 kDa (ZAP-70), which is normally 
expressed in T cells and NK cells. In practice flow 
cytometry turned out to be the preferred technique 
for assaying ZAP-70 expression in CLL cells. Cre-
spo et al. [5] were the first to describe such a flow 
cytometric method, and they confirmed the value 
of ZAP-70 as a surrogate marker for the IgVH muta-
tion status. We determined the level of ZAP-70 using 
the PN 772587 kit from Beckman Coulter, Inc. We had 
defined three levels of change in the parameter: The 
ZAP-70 result corresponds to the norm in interval 
0-10 %. This interval implies a low degree of activity 
of the disease. The result in interval 10–20% corre-
sponds to a boundary region for ZAP-70, this region 
reflects a medium degree of disease.  An increase 
to more than 20% for ZAP-70 corresponds to the high 
degree of disease [6, 7, 11]. Table 1 contains informa-
tion about the distribution of the ZAP-70 levels and the 
degree of activity of the disease. ZAP-70 expression 
was determined by flow cytometry using heparinized 
samples of peripheral blood stored at room tempera-
ture for up to 24 h. After establishing the presence 
of a CD19+/CD5+ population and diagnosis of CLL, 
analysis of ZAP-70 expression was performed. The 
cells were incubated with CD19 (PC5; Beckman-
Coulter, Miami, FL USA) and CD5 (FITC; Beckman-
Coulter, Miami, FL USA) for 15 min. Intraprep reagent 
1 (Beckman Coulter Miami, FL USA) was added and 
incubated for 15 min. After centrifugation and removal 
of the supernatant, Intraprep Reagent 2 (Beckman 
Coulter Miami, FL USA) was added. After gentle vortex-
ing, antibody to ZAP-70 (PE, Beckman-Coulter, Miami, 
FL USA) was added and the sample was incubated 
for an additional 15 min. A parallel patient sample 
was processed identically with fluorochrome labelled 
isotype control antibodies and used to determine the 
background. After centrifugation, removal of the su-
pernatant and re-suspension, the cells were analyzed 
by flow cytometry. The small mononuclear cells were 
gated using forward and right angle scatter. Within this 
population, the CD19+/CD5+ population was selected 
for further analysis. The percentage of cells in this 
population positive for ZAP-70 was determined [14].
Table 1. Level of ZAP-70 and degree of CLL activity
Level of ZAP-70 (%) Degree of activity
0—10 low
10—20 middle
20 and more high
CD38 assay. CD38 expression on leukemic 
lymphocytes was the first marker to be correlated 
with IgVH mutations [23]. Eventually, however, it was 
found that the relationship is not absolute and that, 
according to some studies, CD38 expression may 
vary over time [22]. Recently, it has been found that 
CD38 is expressed on CLL cells [24]. We defined three 
levels of the parameter: the results in the interval from 
0 to 10 % equivalent norm for CD38 parameter or low 
degree of activity of the disease, the interval 10–20 % 
is a boundary region for CD38 and this region cor-
responds to the middle degree of disease. Increase 
of the norm to more than 20% for CD38 corresponds 
to the high degree of disease [3, 22]. Table 2 contains 
information on CD38 expression level and CLL activity. 
We used two reagents, CD23 FITC (Beckman-Coulter, 
Miami, FL USA)  and CD38 PE (Beckman-Coulter, 
Miami, FL USA), incubation time 15 min. A parallel 
patient sample was processed identically with fluoro-
chrome labelled isotype control antibodies and used 
to determine the background. After incubation the 
Immunoprep reagent system was added, and the test 
tubes were processed on a work station, the cells were 
analyzed by flow cytometry [18]. The CD38 was deter-
mined by the Crespo method. CD38 and ZAP-70 were 
determined in the Hematopathology laboratory in the 
Riga Centre of Haematology. Reagents and equip-
ment EPICS XL from Beckman Coulter were used for 
this method.
Table 2. Level of CD38 expression and CLL activity
Level of CD38 (%) Degree of activity
0—10 low
10—20 middle
20 and more high
RESULTS 
The 120 patients enrolled in this study (60 male, 
60 female) had an age range of 34-86 years (median 
67 years). The median age of males and females was 
65.6 and 69.3 years, respectively. The Rai stages were 
as follows (Table 3). Seven patients from the cohort 
of the 120 patients were newly diagnosed with the 
Rai stage 0; 38 were Rai stage I; 40 were Rai stage II; 
19 were Rai stage III; 16 were Rai stage IV. The largest 
subgroup studied therefore was the Rai stage II (see 
Table 3).The Fig. 1 shows the number of patients in all 
CLL stages.
Table 3. Characteristics of the 120 cases studied
Nr Parameter Number
1 Number of cases 120
2 Males/females 60/60
3 Age median/range    (years) 67/34-86
4 Rai 0 stage 7
5 Rai I stage 38
6 Rai II stage 40
7 Rai III stage 19
8 Rai IV stage 16
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Fig. 1. Distribution of CLL patients by Rai stages
For the statistical analysis we divided all of the pa-
tients into three groups: a low risk group, containing 
the patients with the Rai stages 0 and I; a middle risk 
group with patients’ Rai stage II; a high risk group with 
patients from Rai stages III and IV. Table 4 contains infor-
mation about the numbers of patients and their median 
ages in each group. The information in Table 5 and 
Fig. 2 shows the number of patients in each stage within 
the corresponding TK parameters group. The interval 
from 0 to 50ng/L had only one patient, belonging to the 
low risk group. There were 30 patients in the interval 
from 100 to 500ng/L (Rai stages 0—I containing 17 pa-
tients; Rai stage II ― 8; Rai stages III and IV ― 5). There 
were 34 patients in the interval from 501 to 1000 ng/L 
(Rai stages 0-I containing 12 patients; Rai stage II ― 10; 
Rai stages III and IV ― 12). There were 55 patients in the 
interval > 1000ng/L (Rai stages 0-I contain 15 patients; 
Rai stage II ― 22; Rai stages III and IV ― 18). In the 
low risk group the highest number of patients was 
in the interval from 100 to 500 ng/L. In the middle risk 
group the highest count of patients were in the interval 
> 1000 ng/L. The same situation was seen in the high 
risk group. Table 6 and Fig. 3 contain information on the 
parameter ZAP-70. The low risk group (corresponding 
to Rai stages 0 and I) consisted of 45 patients. The group 
of 29 patients belonged to the interval from 0 to 10%. 
The 10 patients were in the interval from 10 to 20% in the 
same group. The interval with level of ZAP-70 > 20% 
in the low risk group contained 6 patients. There were 
40 patients in the middle risk group (corresponding 
to Rai stage II). The interval from 0 to 10% consisted 
of 22 patients. There were 7 patients in the interval from 
10 to 20 % in the same group. The group of 11 patients 
belonged to the interval with a level of ZAP-70 more than 
20%. The 35 patients were in the high risk group (cor-
responding to Rai stages III and IV). The interval from 
0 to 10% contained 20 patients. The 8 patients were 
in the interval from 10 until 20% in the same subgroup, 
and 7 patients ― in the interval more than 20%. Table 
7 and Fig. 4 contain information about the CD38 dis-
tribution between the cohorts of CLL patients divided 
in the groups. There were 29 patients in the interval 
from 0 to 10% in the low risk group (that corresponds 
to Rai stages 0―I). The interval from 10 to 20% con-
tained 12 patients in the same group. The same low risk 
group with the level of CD38 more than 20% consists 
of 4 patients. The intermediate group (that corresponds 
to Rai stage II) contained 23 patients in the interval from 
0 to 10%. Only 7 patients were in a group with the interval 
from 10 to 20%. The group from10 patients were in the 
interval > 20%. In the high risk group (that corresponds 
to Rai stages III—IV) consisted from 25 patients. In the 
interval from 0 to10% were 25 patients. Only 3 patients 
were in the interval from 10 to 20% within the same 
group. The high risk group with the interval more than 
20% included 7 patients. However, each marker con-
sidered individually did not contain important prognostic 
information, the significant correlations between the 
stages and the level of TK (p < 0.05), and between the 
level of CD38 and ZAP-70 (p < 0.001) were observed 
(Table 8).
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Fig. 4. The levels of CD38 in all CLL groups (%) 
Table 4. Distribution of patients between the progression’s groups and 
median ages for each group 
Group of progression stage number of patients mean age+(years)
low 0 and I 45 67.56
middle II 40 67.95
high III and IV 35 66.71
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Group of progression stage number of patients mean age+(years)
total 120 67.44
Table 5. Number and percentage of patients with various levels 
of TK in all stages of CLL
Stage Total0 and I II III and IV
TK (ng/L) 0—50 Number 1 0 0 1
% within stage 2.2 0 0 8
100—500 Number 17 8 5 30
% within stage 37.8 20.0 14.3 25.0
501-1000 Number 12 10 12 34
% within stage 26.7 25.0 34.3 28.3
>1000 Number 15 22 18 55
% within stage 33.3 55.0 51.4 45.8
Total Number 45 40 35 120
% within stage 100.0 100.0 100.0 100.0
Table 6. Number and percentage of patients with the various levels 
of ZAP-70 in all stages of CLL
Stage Total0 and I II III and IV
ZAP-70 0—10% Number 29 22 20 71
% within stage 64.4 55.0 57.1 59.2
10—20% Number 10 7 8 25
% within stage 22.2 17.5 22.9 20.8
>20% Number 6 11 7 24
% within stage 13.3 27.5 20.0 20.0
Total Number 45 40 35 120
% within stage 100.0 100.0 100.0 100.0
Table 7. Absolute number and percentage of patients with the different 
levels of CD38 in all stages of CLL
Stage Total0 and I II III and IV
CD38 0—10% Number 29 23 25 77
% within stage 64.4 57.5 71.4 64.2
10—20% Number 12 7 3 22
% within stage 26.7 17.5 8.6 18.3
>20% Number 4 10 7 21
% within stage 8.9 25.0 20.0 17.5
Total Number 45 40 35 120
% within stage 100.0 100.0 100.0 100.0
Table 8. Correlation between all parameters
Age Gender ZAP-70 CD38 TK Stage
Age p 1 0.1 0.5 -0.1 0.5 -0.5
N 120 120 120 120 120 120
Gender p 0.1 1 -0.5 -0.5 0.5 -0.1
N 120 120 120 120 120 120
ZAP-70 p 0.5 -0.5 1 0.001 0.1 0.1
N 120 120 120 120 120 120
CD38 p -0.1 -0.5 0.001 1 0.5 0.5
N 120 120 120 120 120 120
TK p 0.5 0.5 0.1 0.5 1 0.05
N 120 120 120 120 120 120
Stage p -0.5 -0.1 0.1 0.5 0.05 1
N 120 120 120 120 120 120
Note:  p ― Pearson’s coefficient; N ― total number of patients.
DISCUSSION
Previous reports have recognized the role of se-
rum TK in predicting progression free survival in CLL 
patients. In our report we try to show the relationship 
between the levels of TK and stage of disease for new 
cases of CLL [16, 17, 19]. The aim of this study includes 
investigation of associations between elevated TK levels 
and other markers ―  ZAP-70 and CD38 expression, 
and to ascertain if any parameters were associated with 
elevated TK. Table 8 contains information on correla-
tion between all these parameters. We have based our 
interpretation on earlier published data [26, 27]. As re-
ported previously, some difficulties arise on choosing 
a limit for CD38. In our work, we have selected the limits 
for CD38 and ZAP-70 in the intervals from 0 to 10%, 
from 10% to 20% and > 20%. The level of TK from 
0 to 50ng/L was accepted as a norm (ELISA technique, 
Divi Tum kit, Biovica, Sweden). The positive results for 
TK all are > 100 ng/L. All cases with positive results are 
divided into three groups: from 100ng/L to 500ng/L, 
from 501ng/L to 1000 ng/L and > 1000 ng/L. All new pa-
tients are analyzed and divided into groups. As reported 
previously [23], these limits are chosen empirically 
to compare positive and negative cases. This empirical 
choice is confirmed by Hamblin et al. [8]. In the papers 
[14, 28] information is presented claiming that the eleva-
tion of ZAP-70 level reflects the progression of illness.
As reported by Knauf et al. [29] the increase of TK ac-
tivity is conducive to progress of the disease in the low 
progression group of patients. Our results show that there 
is a correlation between the levels of TK and stages of the 
disease (p < 0.05). Another work [25] indicates that a high 
level of TK induces further progress of the disease in the 
advanced Rai stage. As our report contains only informa-
tion on new patients, we can not offer a prognosis regard-
ing the future progress of the disease. Similar findings are 
presented in some other papers [19, 20, 30]. However, 
in these papers the level of TK in the different groups 
of patients is not taken into account. In our case, three 
parameters are analyzed thus providing more information.
We find that the highest levels of all three markers 
are in the middle progression group of patients. This 
group of patients should be analyzed more care-
fully. We also have identified the correlation between 
CD38 and ZAP-70 (p < 0.001).
There are the same number of patients with the ex-
pression levels of CD38 and ZAP-70 > 20% in the high 
progression group. Also, there is a correlation between 
the stages and the TK level (p < 0.05), however, there 
is no correlation between the stages and ZAP-70 and 
CD38 parameters. When we examine all the parame-
ters, the highest number of patients corresponds to the 
high progression group. The separation of patients 
into prognostically significant groups make possible 
to evaluate the results. In agreement with previous 
reports, the TK levels are found to increase advance-
ment and thus do not lose a predictive potential. This 
is in contrast with the ZAP-70 expression which has 
recently been suggested to loose its discriminating 
ability in advanced clinical stages (Rai) [11, 13].
Our study demonstrates that the value of serum 
TK levels determination along with other markers al-
low to improve risk stratification of patients with CLL 
at diagnosis. However, each marker individually does 
not reveal the complete information. All markers need 
to be assessed in complex.
In conclusion, the estimation of TK, ZAP-70 and 
CD38 parameters together shows that there are cor-
relations between the stages of CLL and the TK level 
(p < 0.05), and between the levels of CD38 and 
ZAP-70 (p < 0.001). The other parameters show 
no significant correlations. Separating the patients into 
three subgroups according to the stages facilitates the 
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statistical analysis. The analysis of TK, ZAP-70 and 
CD38 parameters at diagnosis could identify patients 
for future, more intensive study of these subgroups.
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